Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
New York Stock Exchange
Biotech
Evommune prices IPO amid government shutdown
Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price between $15 and $17 per share.
Gabrielle Masson
Oct 30, 2025 12:34pm
New York Stock Exchange honors Fierce 15 winners
Sep 23, 2025 10:16am
Orthopedic implant maker Shoulder Innovations files $100M+ IPO
Jul 24, 2025 11:00am
Judge rules against investor trying to block Aurion IPO
Jan 28, 2025 2:54pm
Fierce Biotech's Gabrielle Masson presents Fierce 15 at NYSE
Aug 7, 2024 12:00pm
Rockley Photonics files for bankruptcy
Jan 26, 2023 12:21pm
